TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8519378
Drug: Shortened time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shortened time interval between dose steps (3 min)
Study: 30718539
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rTMS and ABM training
Study: 30718539
Drug: ABM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABM treatment
Study: 17364399
Drug: HIV medication
Normalized name: HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV medication adherence
Study: 16289803
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for chronic pain
Study: 12109952
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine (5 mg bolus injections at 5 min intervals)
Study: 10546840
Drug: Intramuscular artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular artemether (3.2‐mg/kg loading dose followed by 1.6 mg/kg daily)
Study: 10546840
Drug: Intravenous quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinine (20‐mg/kg loading dose followed by 10 mg/kg every 8 h)
Study: 8696533
Drug: No lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No lipid-lowering treatment (group C, n = 22)
Study: 8696533
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (group A, n = 52)
Study: 8696533
Drug: No lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No lipid-lowering treatment (group C)
Study: 1978497
Drug: Remoxipride 100-300
Normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride 100-300 mg/day (n = 60)
Study: 1978497
Drug: Remoxipride 200-600
Normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride 200-600 mg/day (n = 61)
Study: 1978497
Drug: Haloperidol 10-30
Normalized name: haloperidol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 10-30 mg/day (n = 64)
Study: 351394
Drug: Aspirin (Men)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (Men)
Study: 351394
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Aspirin and Sulfinpyrazone
Study: 31694579
Drug: Colonoscopy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colonoscopy without prophylactic antibiotics
Study: 26267731
Drug: Methotrexate (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (up to 25 mg/week orally)
Study: 21331473
Drug: Fast-dissolving azithromycin
Normalized name: melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fast-dissolving azithromycin gelatin capsules
Study: 21331473
Drug: Commercial azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Commercial azithromycin gelatin capsules
Study: 16983108
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m2 every 3 weeks
Study: 15090933
Drug: Riluzole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole (50 mg bid)
Study: 8148228
Drug: Yohimbine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (10 mg)
Study: 8148228
Drug: Yohimbine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (4 mg)
Study: 2844548
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) (all doses)
Study: 21386999
Drug: Adenosine A(2A)
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine A(2A) receptor binding ability measured using [(11)C]TMSX PET in dyskinetic PD patients
Study: 21386999
Drug: Adenosine A(2A)
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine A(2A) receptor binding ability measured using [(11)C]TMSX PET in drug-naïve PD patients
Study: 21386999
Drug: Adenosine A(2A)
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine A(2A) receptor binding ability measured using [(11)C]TMSX PET after antiparkinsonian therapy in drug-naïve PD patients
Study: 18200673
Drug: 100 mL/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL/d of 20% alanyl-glutamine dipeptide (AGD) intravenously for 10 days (early treatment group)
Study: 17186738
Drug: Medicated bath
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicated bath plus acupoint massage (B-M treatment)
Study: 1629993
Drug: Drug treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatments for PTSD
Study: 6512252
Drug: Isopropyl alcohol
Normalized name: Isopropyl Alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isopropyl alcohol skin preparation
Study: 6512252
Drug: 0.5% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% chlorhexidine in 70% spirit skin preparation
Study: 23046499
Drug: Dietary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary and lifestyle advice, monitoring of blood glucose, and further medical treatment for hyperglycaemia as appropriate.
Study: 20329570
Drug: Oxycodone controlled-release
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone controlled-release (CR) administered orally twice daily for at least 28 days, dosage individualized and up-titrated over the first week.
Study: 20329570
Drug: Oxycodone controlled-release
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone controlled-release (CR)
Study: 16845791
Drug: Diacerein (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacerein (100 mg/d)
Study: 16845791
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (75 mg/d)
Study: 1617932
Drug: roxithromycin 150
Normalized name: roxithromycin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin 150 mg twice daily
Study: 1617925
Drug: erythromycin 1
Normalized name: erythromycin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: erythromycin 1 g twice daily
Study: 6150717
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg famotidine daily for 5 days
Study: 6150717
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg cimetidine daily for 5 days
Study: 25358916
Drug: Treatment initiation
Normalized name: Otezla 10mg-20mg 28-Day Treatment Initiation Pack Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment initiation (pharmacotherapy and/or psychotherapy)
Study: 25358916
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (pharmacotherapy and psychotherapy)
Study: 23154888
Drug: Levothyroxine oral
Normalized name: levothyroxine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine oral solution (600 mcg)
Study: 23154888
Drug: Levothyroxine tablets
Normalized name: levothyroxine Oral Tablet
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine tablets (600 mcg)
Study: 23154888
Drug: Levothyroxine soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine soft gel capsules (600 mcg)
Study: 20054522
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment group (CON)
Study: 15814044
Drug: 2 days
Normalized name: Chapstick 12 Days of Christmas KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 days of oral ofloxacin (10 mg/kg/day)
Study: 15814044
Drug: 3 days
Normalized name: Transderm Scop 1mg/3 days Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 days of oral ofloxacin (10 mg/kg/day)
Study: 8606849
Drug: Albuterol aerosol
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol aerosol therapy
Study: 8606849
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CF patients not receiving albuterol therapy)
Study: 28862017
Drug: Adherence support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence support and nutritious food supplement
Study: 27688102
Drug: Panitumumab +
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab + docetaxel/cisplatin chemotherapy
Study: 27688102
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (docetaxel/cisplatin)
Study: 15678730
Drug: 0.1% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% ropivacaine with fentanyl 2 microg mL(-1) at 10 mL h(-1) (Group R1, n = 38)
Study: 15678730
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine with fentanyl 2 microg mL(-1) at 8 mL h(-1) (Group R2, n = 39)
Study: 11770217
Drug: Economic assessment
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Economic assessment of treatments for lung cancer
Study: 9640992
Drug: High-dose alprazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose alprazolam
Study: 9640992
Drug: Low-dose alprazolam
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose alprazolam
Study: 9640992
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment with high-dose alprazolam
Study: 9640992
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment with lorazepam
Study: 9640992
Drug: Single high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high and low doses of alprazolam and lorazepam
Study: 8136599
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine plus normal saline solution
Study: 8136599
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine plus sodium bicarbonate solution
Study: 2685688
Drug: Vindesine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindesine (3 mg/m2 i.v.) and Mitoxantrone (10 mg/m2 i.v.) every 3 weeks x 3 and every 4 weeks thereafter (VM)
Study: 2685688
Drug: Vindesine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindesine (3 mg/m2 i.v.) and Epirubicin (40 mg/m2 i.v.) every 3 weeks x 3 and every 4 weeks thereafter (VE)
Study: 28406648
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (n = 119)
Study: 28406648
Drug: Dynamic therapy
Normalized name: AVOBENZONE 3 g in 100 mL / OCTINOXATE 7.5 g in 100 mL / OCTISALATE 5 g in 100 mL / OXYBENZONE 6 g in 100 mL TOPICAL LOTION [PHOTO DYNAMIC THERAPY SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic therapy (n = 118)
Study: 23715669
Drug: Colloid administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid administration (41 patients)
Study: 23715669
Drug: No colloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No colloid administration (82 patients)
Study: 19223438
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (adjunctive)
Study: 19223438
Drug: Benzodiazepines (adjunctive,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepines (adjunctive, N=10)
Study: 16512804
Drug: Synbiotics (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotics (1.2 x 10^9 CFU Lactobacillus rhamnosus Lcr35 plus prebiotic preparation)
Study: 16512804
Drug: Prebiotics alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotics alone (identically appearing prebiotic preparation)
Study: 22762855
Drug: Generic rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic rosuvastatin 40 mg tablet (Zentiva)
Study: 22762855
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (Generic and Reference)
Study: 17921912
Drug: Valacyclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 500 mg qd
Study: 15893095
Drug: Anabolic steroid
Normalized name: Anabolic steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anabolic steroid prevention program
Study: 12789994
Drug: Colgate Simply
Normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colgate Simply White Clear Whitening Gel (18% carbamide peroxide), applied for 30 minutes, twice daily, for 3 weeks.
Study: 12789994
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (control group).
Study: 9585288
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg of midazolam plus 75 microg of fentanyl
Study: 9585288
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of saline
Study: 2554716
Drug: Danpro-S (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danpro-S (0.8 g.kg‐1.d‐1)
Study: 2554716
Drug: Danprotex-H 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danprotex-H 40 (0.8 g.kg‐1.d‐1)
Study: 489192
Drug: BM 15.100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BM 15.100 (20 mg, single oral dose, administered 60 min prior to allergen inhalation)
Study: 489192
Drug: BM 15.000
Approvals — FDA: no, EMA: no, PMDA: no
Description: BM 15.000 (10 mg)
Study: 29641737
Drug: One time
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time high dose 300,000 IU of ergocalciferol (VD2)
Study: 25586124
Drug: Propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3 mg · kg(‐1) over 3 min
Study: 18972900
Drug: Dexpanthenol spray
Normalized name: Dexpanthenol
DrugBank: Dexpanthenol (DB09357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexpanthenol spray (Mar plus)
Study: 11109181
Drug: Domiciliary chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domiciliary chemotherapy
Study: 11109181
Drug: Hospital-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital-based chemotherapy
Study: 8941405
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2/wk
Study: 8941405
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m2/wk
Study: 1604414
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose pulse methotrexate (MTX, 5‐7.5mg/week)
Study: 4055545
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 500 mg tid (open study)
Study: 4055545
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 500 mg bd (comparative study)
Study: 4055545
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 500 mg tid (comparative study)
Study: 4055545
Drug: Amoxycillin 500
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 500 mg tid (comparative study)
Study: 30747025
Drug: Intracervical Foley
Normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical Foley catheter combined with dinoprostone gel (0.5 mg) for 12 hours followed by oxytocin
Study: 28373691
Drug: Doxycycline (MMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (MMP inhibitor), dosage and duration not specified
Study: 25149295
Drug: 1-L polyethylene
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-L polyethylene glycol and four tablets of bisacodyl with 90 mL of Iopamidol on the same day as CTC examination (group 1)
Study: 25149295
Drug: Standard 'iodine-only'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 'iodine-only' preparation, consisting of 180 mL of Iopamidol the day before the examination (group 2)
Study: 20008774
Drug: 0.5% Glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% Glycerol monolaurate (GML) gel
Study: 20008774
Drug: 5% Glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Glycerol monolaurate (GML) gel
Study: 20008774
Drug: 0% Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0% Control gel
Study: 20008774
Drug: Control and
Normalized name: DIMETHICONE 0.58 mL in 45 mL CUTANEOUS CREAM [SUPER CREAM AGE CONTROL AND FIRMING]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control and GML gels
Study: 18957013
Drug: Intraperitoneal heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal heparin (specifically low-molecular weight heparin)
Study: 18957013
Drug: Intraperitoneal heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal heparin
Study: 15777683
Drug: 6007C >
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6007C > T polymorphism (TT vs. CC)
Study: 15777683
Drug: 6007C >
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6007C > T polymorphism (CT vs. CC)
Study: 12456902
Drug: Steroid (prednisolone)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steroid (prednisolone) + amoxicillin for 14 days, then amoxicillin for 14 more days
Study: 12456902
Drug: Steroid (prednisolone)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steroid (prednisolone) + amoxicillin for 14 days, then placebo for amoxicillin for 14 more days
Study: 12456902
Drug: Placebo (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for steroid) + amoxicillin for 14 days, then amoxicillin for 14 more days
Study: 12456902
Drug: Placebo (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for steroid) + amoxicillin for 14 days, then placebo for amoxicillin for 14 more days
Study: 12456902
Drug: Steroid +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid + amoxicillin
Study: 12456902
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + amoxicillin
Study: 10651262
Drug: Troglitazone 400
Normalized name: troglitazone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 400 mg daily for 16 weeks
Study: 7734716
Drug: NHL855 protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: NHL855 protocol consisting of vincristine, prednisolone, cyclophosphamide, doxorubicin, high-dose methotrexate (HD-MTX), mercaptopurine, cytarabine, CNS prophylaxis with intrathecal MTX and hydrocortisone.
Study: 29880847
Drug: Twice or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice or three times 100 mg aspirin daily dosing
Study: 29880847
Drug: Long-term persistence
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term persistence of superior biochemical efficacy with multiple dosing
Study: 18362499
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement therapy for 2 years
Study: 22011460
Drug: Fish-oil capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil capsules (1720 mg DHA and 600 mg EPA daily)
Study: 12376165
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (triphasic OCs)
Study: 9669832
Drug: Albuterol inhaled
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol inhaled as a microfine powder
Study: 12145664
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with ribavirin
Study: 12145664
Drug: Pegylated therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated therapy
Study: 12145664
Drug: Pegylated combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated combination therapy with high dose ribavirin
Study: 12145664
Drug: Sustained responders
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained responders regardless of therapy
Study: 12145664
Drug: Pegylated combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated combination therapy
Study: 24786931
Drug: IV golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV golimumab 2 mg/kg + MTX
Study: 15655049
Drug: alpha‐interferon (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐interferon (3 MU thrice weekly) + ribavirin (1000‐1200 mg/day) for 48 weeks
Study: 15655049
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (current standard management)
Study: 12369033
Drug: Subcutaneous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous lidocaine (0.2 mL 1%) by jet injector
Study: 12369033
Drug: No anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anesthetic with a sham injection
Study: 1977029
Drug: High-dose Edmonston-Zagreb
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Edmonston-Zagreb (EZ) measles vaccine
Study: 1977029
Drug: Conventional Schwarz
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Schwarz vaccine
Study: 28323627
Drug: CCXG injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCXG injection (100 mL, intravenous drips, 3 times a day)